Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Based on available evidence, dermatologists should at least discuss biologic drugs with patients who have moderate-to-severe psoriasis and cardiovascular comorbidities. Clearing the skin may improve cardiovascular disease, says an expert.
Microbial colonization in the development of inflammatory conditions and immune-mediated conditions is a hot research topic, and new dermatologic therapies can potentially result from greater understanding of the role of microbial communities on the skin and in the gut.
For patients who need or want alternative approaches for treating psoriasis, balenotherapy, curcumin, indigo naturalis, fish oil supplementation, and dietary control may provide effective relief, either alone or as integrative therapy.
With the recent discoveries of immunologic pathways leading to psoriasis, clinicians are likely to discount older general immunosuppressive agents in favor of newer larger molecules like biologics that provide better targeted therapy.
The goal of this activity is to educate pharmacists and pharmacy technicians about pharmacist interventions in improving the quality of life for patients with psoriasis and psoriatic arthritis. Readers will also gain knowledge about available options for treatment, adverse
effects, risks, and benefits.
There’s good evidence to suggest dermatologists who assess psoriasis patients should look beyond the plaques on the skin and consider not just the increased risk to the joints, but also the heart, mind and more.